[go: up one dir, main page]

AU2002334355A1 - Protein tyrosine kinase inhibitors - Google Patents

Protein tyrosine kinase inhibitors

Info

Publication number
AU2002334355A1
AU2002334355A1 AU2002334355A AU2002334355A AU2002334355A1 AU 2002334355 A1 AU2002334355 A1 AU 2002334355A1 AU 2002334355 A AU2002334355 A AU 2002334355A AU 2002334355 A AU2002334355 A AU 2002334355A AU 2002334355 A1 AU2002334355 A1 AU 2002334355A1
Authority
AU
Australia
Prior art keywords
tyrosine kinase
kinase inhibitors
protein tyrosine
protein
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002334355A
Inventor
Oren Bogin
Doron Eren
David Pe'er
Avner Yayon
Andrea Zaliani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prochon Biotech Ltd
Original Assignee
Prochon Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL14532901A external-priority patent/IL145329A0/en
Application filed by Prochon Biotech Ltd filed Critical Prochon Biotech Ltd
Publication of AU2002334355A1 publication Critical patent/AU2002334355A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002334355A 2001-09-06 2002-09-05 Protein tyrosine kinase inhibitors Abandoned AU2002334355A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31718601P 2001-09-06 2001-09-06
US60/317,186 2001-09-06
IL145329 2001-09-09
IL14532901A IL145329A0 (en) 2001-09-09 2001-09-09 Protein tyrosine kinase inhibitors
PCT/IL2002/000740 WO2003020698A2 (en) 2001-09-06 2002-09-05 Protein tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
AU2002334355A1 true AU2002334355A1 (en) 2003-03-18

Family

ID=26324042

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002334355A Abandoned AU2002334355A1 (en) 2001-09-06 2002-09-05 Protein tyrosine kinase inhibitors

Country Status (2)

Country Link
AU (1) AU2002334355A1 (en)
WO (1) WO2003020698A2 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1587821T6 (en) 2002-12-19 2025-05-26 Scripps Research Inst Compositions and methods for stabilizing trans-thyretin and inhibiting transthyretin misfolding
EP1631291B1 (en) 2003-05-27 2009-08-12 Robert P. Hägerkvist Use of tyrosine kinase inhibitors to treat diabetes
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
SG131944A1 (en) * 2003-08-21 2007-05-28 Osi Pharm Inc N3-substituted imidazopyridine-derivatives as c-kit inhibitors
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
AU2004308299B2 (en) * 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
AU2005245470A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7960548B2 (en) * 2005-04-29 2011-06-14 The Ohio State University Research Foundation Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
JP2008543855A (en) 2005-06-13 2008-12-04 ライジェル ファーマシューティカルズ， インコーポレイテッド Methods and compositions for treating degenerative bone disease
US8334290B2 (en) 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
EP1966157B1 (en) 2005-11-15 2010-03-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2385849T3 (en) 2006-05-02 2012-08-01 Abbott Laboratories The substituted 1H-benzimidazol-4-carboxamides are potent inhibitors of PARP
EP1860104A1 (en) * 2006-05-22 2007-11-28 Aptanomics Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008070599A1 (en) * 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
MX2010000617A (en) 2007-07-17 2010-05-17 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
LT2265607T (en) 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
MA33975B1 (en) 2009-11-06 2013-02-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASES AND THEIR INDICATIONS FOR USE
ES2628418T3 (en) 2010-05-20 2017-08-02 Array Biopharma, Inc. Macrocyclic compounds as inhibitors of TRK kinase
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
HUE040136T2 (en) 2011-02-07 2019-02-28 Plexxikon Inc Compounds and Methods for Kinase Modulation and Their Indications
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
CN103781770B (en) 2011-09-16 2016-04-13 辉瑞公司 Transthyretin dissociates the solid form of inhibitor
JP6039683B2 (en) 2011-11-23 2016-12-07 ポートラ ファーマシューティカルズ， インコーポレイテッド Pyrazine kinase inhibitor
CN105646517A (en) * 2012-03-22 2016-06-08 巴塞利亚药业（中国）有限公司 Preparation methods of natural product Hirtellanine B and derivatives thereof and application of natural product Hirtellanine B and derivatives thereof in preparation of drug for treating tumor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
GB201223265D0 (en) * 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI876442B (en) 2017-10-10 2025-03-11 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN119909072A (en) * 2025-01-24 2025-05-02 中国人民解放军空军军医大学 Application of benzofurano[3,2-c]quinolinone compounds in preventing and treating fatty liver disease associated with metabolic dysfunction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199800127T1 (en) * 1995-08-02 1998-04-21 Newcastle University Ventures Limited Benzimidazole bile�ikleri.
DE59911249D1 (en) * 1998-11-03 2005-01-13 Abbott Gmbh & Co Kg SUBSTITUTED 2-PHENYLBENZIMIDAZOLE, THEIR PREPARATION AND APPLICATION

Also Published As

Publication number Publication date
WO2003020698A2 (en) 2003-03-13
WO2003020698A3 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
AU2003299651A1 (en) Tyrosine kinase inhibitors
EP1381598A4 (en) Novel tyrosine kinase inhibitors
AU2003298942A1 (en) Tyrosine kinase inhibitors
HUP0400300A3 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2003282891A1 (en) Novel tyrosine kinases inhibitors
AU2002357193A1 (en) Thienopyrimidine compounds as protein tyrosine kinase inhibitors
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2003275282A1 (en) Novel tyrosine kinase inhibitors
IL159506A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2002953255A0 (en) Protein kinase inhibitors
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2576501A (en) Protein kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AUPS251502A0 (en) Protein kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
HK1079196A (en) Protein tyrosine kinase inhibitors
AU2002327619A1 (en) Tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase